3(d) or Not 3(d): That Is the Question Delhi HC Refuses to Answer – For Now
Daewoong Pharmaceutical challenged the Controller's rejection of its crystalline SGLT inhibitor patent before the Delhi High Court. The core question: does improved dissolution and stability satisfy the Section 3(d) threshold for enhanced therapeutic efficacy? The court remanded the matter, finding…









